NCT07209761

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-10-16Est. Completion: 2028-09-29

Enrollment target: 532 participants

Locations

Capital Medical University - Beijing Chest Hospital, Beijing, Beijing Municipality, China
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province, Fuzhou, Fujian, China
The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China
Wuhan Institute of Tuberculosis Control (Wuhan Pulmonary Hospital), Wuhan, Hubei, China
The Second Hospital of Nanjing, Nanjing, Jiangsu, China
Shandong Public Health Clinical Center, Jinan, Shandong, China
Huashan Hospital Fudan University, Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital - Pneumology, Shanghai, Shanghai Municipality, China
Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China
National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia
P.D. Hinduja Hospital & Medical Research Centre - MAHIM, Mumbai, Maharashtra, India
Rajan Babu Institute of Pulmonary Medicine and Tuberculosis (RBIPMT) - RBTB Hospital, New Delhi, National Capital Territory of Delhi, India
National Institute of Tuberculosis and Respiratory Diseases Hospital (NITRD), New Delhi, National Capital Territory of Delhi, India

Tuberculosis (TB)

People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggesti…

Islamabad, PakistanEst. completion Nov 2028

TuberculosisHuman Immunodeficiency Virus

Tuberculosis (TB) remains a major global public health problem, particularly in low- and middle-income countries (LMICs)…

Moshi, TanzaniaCompleted May 25, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.